Structure-activity relationship studies on tetralin carboxamide growth hormone secretagogue receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 7, 2005, Pages 1825-1828

  Zhao, Hongyu ^a   Xin, Zhili ^a   Patel, Jyoti R ^a   Nelson, Lissa T J ^a   Liu, Bo ^a   Szczepankiewicz, Bruce G ^a   Schaefer, Verlyn G ^a   Falls, H Douglas ^a   Kaszubska, Wiweka ^a   Collins, Christine A ^a   Sham, Hing L ^a   Liu, Gang ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antagonist; Ghrelin; SAR

Indexed keywords

AMIDE; GROWTH HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; TETRALIN DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 20144366836     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.02.026     Document Type: Article

References (15)

1. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa Nature 402 1999 656
2. A.M. Wren, C.J. Small, H.L. Ward, K.G. Murphy, C.L. Dakin, S. Taheri, A.R. Kennedy, G.H. Roberts, D.G. Morgan, M.A. Ghatei, and S.R. Bloom Endocrinology 141 2000 4325
3. A.M. Wren, C.J. Small, C.R. Abbott, W.S. Dhillo, L.J. Seal, M.A. Cohen, R.L. Batterham, S. Taheri, S.A. Stanley, M.A. Ghatei, and S.R. Bloom Diabetes 50 2001 2540
4. A.M. Wren, L.J. Seal, M.A. Cohen, A.E. Brynes, G.S. Frost, K.G. Murphy, W.S. Dhillo, M.A. Ghatei, and S.R. Bloom J. Clin. Endocrinol. Metab. 86 2001 5992
5. N. Murakami, T. Hayashida, T. Kuroiwa, K. Nakahara, T. Ida, M.S. Mondal, M. Nakazato, M. Kojima, and K. Kangawa J. Endocrinol. 174 2002 283
6. A. Asakawa, A. Inui, T. Kaga, G. Katsuura, M. Fujimiya, M.A. Fujino, and M. Kasuga Gut 52 2003 947
7. C.W. Lugar, M.P. Clay, T.D. Lindstrom, A.L. Woodson, D. Smiley, M.L. Heiman, and J.A. Dodge Bioorg. Med. Chem. Lett. 14 2004 5873
8. K. Cheng, W.W.S. Chan, B. Butler, L. Wei, and R.G. Smith Horm. Res. 40 1993 109
9. B. Liu, G. Liu, Z. Xin, M.D. Serby, H. Zhao, V.G. Schaefer, D.H. Falls, W. Kaszubska, C.A. Collins, and H.L. Sham Bioorg. Med. Chem. Lett. 14 2004 5223
10. H. Zhao, Z. Xin, G. Liu, V.G. Schaefer, H.D. Falls, W. Kaszubska, C.A. Collins, and H.L. Sham J. Med. Chem. 47 2004 6655
11. For assay conditions see Ref. 8
12. Only a 4-fold loss of potency was observed for the same modification in the isoxazole carboxamide series. See Ref. 8
13. For the isoxazole carboxamide GHS-R antagonists, replacing the phenylenediamine group with a cyclohexyl diamine group resulted in compounds with much-improved aqueous solubility. See Ref. 8
14. P.S. Burton, J.T. Goodwin, T.J. Vidmar, and B.M. Amore J. Pharmacol. Exp. Ther. 303 2002 889
15. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Adv. Drug Delivery Rev. 23 1997 3